Harvard Bioscience Reports Q4 Preliminary Revenue Of $23.7M

Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter ended December 31, 2025. In conjunction with these results, the Company outlined a cohesive long-term strategy designed to leverage its market-leading portfolio to drive sustainable growth and increase shareholder value.

Preliminary Fourth Quarter 2025 Financial Highlights
Based on preliminary unaudited information, the Company expects to report:

• Revenue of $23.7 million, above the midpoint of the $22.5 million to $24.5 million guidance range.
• Gross Margin of 60%, at the high end of the 58% to 60% guidance range, driven by an improved mix to higher margin product lines, as well as the benefit of prior cost reductions.